| Year |
Citation |
Score |
| 2024 |
Charou D, Rogdakis T, Latorrata A, Valcarcel M, Papadogiannis V, Athanasiou C, Tsengenes A, Papadopoulou MA, Lypitkas D, Lavigne MD, Katsila T, Wade RC, Cader MZ, Calogeropoulou T, Gravanis A, et al. Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer's disease. Stem Cell Research & Therapy. 15: 200. PMID 38971770 DOI: 10.1186/s13287-024-03818-w |
0.621 |
|
| 2023 |
Schimunek J, Seidl P, Elez K, Hempel T, Le T, Noé F, Olsson S, Raich L, Winter R, Gokcan H, Gusev F, Gutkin EM, Isayev O, Kurnikova MG, Narangoda CH, ... ... Tsengenes A, et al. A community effort in SARS-CoV-2 drug discovery. Molecular Informatics. PMID 37833243 DOI: 10.1002/minf.202300262 |
0.504 |
|
| 2023 |
Claveras Cabezudo A, Athanasiou C, Tsengenes A, Wade RC. Scaling Protein-Water Interactions in the Martini 3 Coarse-Grained Force Field to Simulate Transmembrane Helix Dimers in Different Lipid Environments. Journal of Chemical Theory and Computation. PMID 36821400 DOI: 10.1021/acs.jctc.2c00950 |
0.617 |
|
| 2022 |
Rogdakis T, Charou D, Latorrata A, Papadimitriou E, Tsengenes A, Athanasiou C, Papadopoulou M, Chalikiopoulou C, Katsila T, Ramos I, Prousis KC, Wade RC, Sidiropoulou K, Calogeropoulou T, Gravanis A, et al. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity. Biomedicines. 10. PMID 35327415 DOI: 10.3390/biomedicines10030614 |
0.629 |
|
| Show low-probability matches. |